ATE323705T1 - Substituierte indolizinähnliche verbindungen und ihre verwendung - Google Patents

Substituierte indolizinähnliche verbindungen und ihre verwendung

Info

Publication number: ATE323705T1
Authority: AT; Austria
Prior art keywords: compounds; diseases; maladies; diabetes; pain
Prior art date: 2001-11-16

Application number

AT02789671T

Other languages

English (en)

Inventor

Guolin Cai

Jennifer N Chau

Celia Dominguez

Gilbert M Rishton

Yuelie Lu

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-16

Filing date

2002-11-16

Publication date

2006-05-15

2002-11-16 Application filed by Amgen Inc filed Critical Amgen Inc

2006-05-15 Application granted granted Critical

2006-05-15 Publication of ATE323705T1 publication Critical patent/ATE323705T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 4
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 2
208000002193 Pain Diseases 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
-1 IL-1beta Proteins 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
108090001005 Interleukin-6 Proteins 0.000 abstract 1
102000004890 Interleukin-8 Human genes 0.000 abstract 1
108090001007 Interleukin-8 Proteins 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Endocrinology (AREA)

AT02789671T 2001-11-16 2002-11-16 Substituierte indolizinähnliche verbindungen und ihre verwendung ATE323705T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33244701P	2001-11-16	2001-11-16
US10/298,205 US6921762B2 (en)	2001-11-16	2002-11-15	Substituted indolizine-like compounds and methods of use

Publications (1)

Publication Number	Publication Date
ATE323705T1 true ATE323705T1 (de)	2006-05-15

Family

ID=26970531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02789671T ATE323705T1 (de)	2001-11-16	2002-11-16	Substituierte indolizinähnliche verbindungen und ihre verwendung

Country Status (14)

Country	Link
US (1)	US6921762B2 (de)
EP (1)	EP1448564B1 (de)
JP (1)	JP2005518358A (de)
AT (1)	ATE323705T1 (de)
AU (1)	AU2002352722B2 (de)
CA (1)	CA2466072A1 (de)
CY (1)	CY1105053T1 (de)
DE (1)	DE60210805T2 (de)
DK (1)	DK1448564T3 (de)
ES (1)	ES2262879T3 (de)
MX (1)	MXPA04004552A (de)
PL (1)	PL371428A1 (de)
PT (1)	PT1448564E (de)
WO (1)	WO2003044021A2 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL378402A1 (pl) *	2003-02-06	2006-04-03	Basf Aktiengesellschaft	Pirymidyny, sposoby ich wytwarzania i ich zastosowanie
JP2006517580A (ja) *	2003-02-14	2006-07-27	ファイザー・プロダクツ・インク	抗炎症化合物としてのトリアゾロピリジン
US7582631B2 (en) *	2004-01-14	2009-09-01	Amgen Inc.	Substituted heterocyclic compounds and methods of use
KR100871535B1 (ko) *	2004-08-12	2008-12-05	화이자 인코포레이티드	Ｐ38 ｍａｐ 키나아제 억제제로서의트리아졸로피리딘일설판일 유도체
DE602005010714D1 (de) *	2004-08-12	2008-12-11	Pfizer	Der p38-map-kinase
US20090215817A1 (en) *	2004-08-18	2009-08-27	Pfizer Inc	Novel Triazolopyridine Compounds for the Treatment of Inflammation
JP2008509987A (ja) *	2004-08-18	2008-04-03	ファルマシアアンドアップジョンカンパニーリミテッドライアビリティカンパニー	トリアゾロピリジン化合物
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006073938A2 (en) *	2004-12-30	2006-07-13	East Carolina University	Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR20100065191A (ko)	2007-09-14	2010-06-15	오르토-맥닐-얀센 파마슈티칼스 인코포레이티드	１,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
CA2696948C (en)	2007-09-14	2013-04-30	Jose Maria Cid-Nunez	1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
WO2009082691A1 (en) *	2007-12-21	2009-07-02	Board Of Regents, University Of Texas System	Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
CA2735764C (en)	2008-09-02	2016-06-14	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt)	2008-11-28	2015-12-29	Addex Pharmaceuticals Sa	derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
NZ596078A (en)	2009-05-12	2013-06-28	Janssen Pharmaceuticals Inc	1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EA020671B1 (ru)	2009-05-12	2014-12-30	Янссен Фармасьютикалз, Инк.	ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2762680C (en)	2009-05-21	2018-04-17	Chlorion Pharma, Inc.	Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
WO2011089400A1 (en)	2010-01-22	2011-07-28	Centro Nacional De Investigaciones Oncológicas (Cnio)	Inhibitors of pi3 kinase
TW201200518A (en) *	2010-03-10	2012-01-01	Kalypsys Inc	Heterocyclic inhibitors of histamine receptors for the treatment of disease
EP2560488B1 (de)	2010-04-23	2015-10-28	Cytokinetics, Inc.	Bestimmte aminopyrimidine und aminotriazine, zusammensetzungen daraus und verfahren zu ihrer verwendung
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011141713A1 (en)	2010-05-13	2011-11-17	Centro Nacional De Investigaciones Oncologicas (Cnio)	New bicyclic compounds as pi3-k and mtor inhibitors
CA2815002C (en)	2010-11-08	2019-10-22	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298810B (zh)	2010-11-08	2016-03-16	杨森制药公司	1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2643320B1 (de)	2010-11-08	2015-03-04	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors
DK2748147T3 (da) *	2011-08-25	2017-11-13	St Jude Children's Res Hospital	Substitueret 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4-tetrahydroisoquinolin-4-carboxamider til antimalaria-terapier
WO2013082458A1 (en)	2011-12-02	2013-06-06	The Regents Of The University Of California	Reperfusion protection solution and uses thereof
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX375902B (es) *	2013-12-30	2025-03-07	Genentech Inc	Inhibidores de serina/treonina cinasa.
LT3431106T (lt)	2014-01-21	2021-02-10	Janssen Pharmaceutica Nv	Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko)	2014-01-21	2022-06-27	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
KR102421235B1 (ko)	2014-02-13	2022-07-15	인사이트 코포레이션	Lsd1 저해제로서 사이클로프로필아민
EP3392244A1 (de)	2014-02-13	2018-10-24	Incyte Corporation	Cyclopropylamine als lsd1-inhibitoren
NZ723203A (en)	2014-02-13	2020-08-28	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
WO2016007731A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en)	2014-07-10	2017-09-12	Incyte Corporation	Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
CN107108637B (zh)	2014-12-23	2019-10-29	诺华股份有限公司	三唑并嘧啶化合物及其用途
UA122688C2 (uk)	2015-04-03	2020-12-28	Інсайт Корпорейшн	Гетероциклічні сполуки як інгібітори lsd1
JP7427363B2 (ja)	2015-08-12	2024-02-05	インサイト・ホールディングス・コーポレイション	Ｌｓｄ１阻害剤の塩
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10166221B2 (en)	2016-04-22	2019-01-01	Incyte Corporation	Formulations of an LSD1 inhibitor
IL263429B (en)	2016-06-20	2022-08-01	Novartis Ag	Crystalline forms of triazolopyrimidine compound
WO2017221092A1 (en)	2016-06-20	2017-12-28	Novartis Ag	Triazolopyridine compounds and uses thereof
US10676479B2 (en)	2016-06-20	2020-06-09	Novartis Ag	Imidazolepyridine compounds and uses thereof
PH12019500056B1 (en)	2016-07-12	2024-01-31	Revolution Medicines Inc	2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
BR112019015075A2 (pt)	2017-01-23	2020-03-10	Revolution Medicines, Inc.	Compostos bicíclicos como inibidores de shp2 alostéricos
SG11201906412SA (en)	2017-01-23	2019-08-27	Revolution Medicines Inc	Pyridine compounds as allosteric shp2 inhibitors
JP6934562B2 (ja)	2017-08-22	2021-09-15	ギリアードサイエンシーズ，インコーポレイテッド	治療用複素環式化合物
SG11202002941WA (en)	2017-10-12	2020-04-29	Revolution Medicines Inc	Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) *	2017-12-15	2019-06-20	Revolution Medicines, Inc.	Polycyclic compounds as allosteric shp2 inhibitors
NZ766447A (en) *	2018-01-31	2021-12-24	Mirati Therapeutics Inc	Prc2 inhibitors
CN115448923B (zh) *	2018-02-13	2024-03-22	上海青煜医药科技有限公司	嘧啶并环化合物及其制备方法和应用
MA51845A (fr) *	2018-02-13	2020-12-23	Shanghai Blueray Biopharma Co Ltd	Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application
BR122023024273A2 (pt) *	2018-02-27	2024-02-20	Incyte Corporation	Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3810610A1 (de)	2018-05-18	2021-04-28	Incyte Corporation	Kondensierte pyrimidinderivate als a2a/a2b-inhibitoren
AU2019297361B2 (en)	2018-07-05	2024-06-27	Incyte Corporation	Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020047198A1 (en)	2018-08-31	2020-03-05	Incyte Corporation	Salts of an lsd1 inhibitor and processes for preparing the same
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP3950064A4 (de) *	2019-04-03	2023-01-04	Tera Stone Co., Ltd	Auf thyminnukleobase basierende triazolopyrimidine und verfahren zu ihrer herstellung
JP7624404B2 (ja)	2019-04-22	2025-01-30	ミラティセラピューティクス，インク．	Ｐｒｃ２阻害剤としてのナフチリジン誘導体
AU2020288563A1 (en)	2019-06-05	2022-01-06	Mirati Therapeutics, Inc.	Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer
CN110551123A (zh) *	2019-07-23	2019-12-10	常州合全药业有限公司	一种5-(叔丁氧羰基)-2-甲基-4,5,6,7-四氢-2h-吡唑并[4,3-c]吡啶-7-羧酸的制备方法
WO2024119067A1 (en)	2022-12-02	2024-06-06	Neumora Therapeutics, Inc.	Methods of treating neurological disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE3402194A1 (de) *	1984-01-24	1985-07-25	Bayer Ag, 5090 Leverkusen	Verfahren zur selektiven hydrierung von chlor enthaltenden pyrimidinen und neue pyrimidine
US5229519A (en)	1992-03-06	1993-07-20	Reilly Industries, Inc.	Process for preparing 2-halo-5-halomethylpyridines
US5691196A (en) *	1992-12-31	1997-11-25	American Cyanamid Company	Recombinant nucleic acid containing a response element
CZ289317B6 (cs)	1994-04-11	2002-01-16	Sankyo Company Limited	Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2306108A (en)	1995-10-13	1997-04-30	Merck & Co Inc	Treatment of Raf-mediated cancers with imidazole derivatives
WO1997016442A1 (en)	1995-10-31	1997-05-09	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR038955A1 (es)	1996-12-05	2005-02-02	Amgen Inc	Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
US6096753A (en)	1996-12-05	2000-08-01	Amgen Inc.	Substituted pyrimidinone and pyridone compounds and methods of use
HUP0001140A3 (en)	1996-12-05	2002-05-28	Amgen Inc Thousand Oaks	Substituted pyrimidinone and pyridone compounds and methods of use
JP2000307470A (ja)	1999-04-16	2000-11-02	Matsushita Electric Ind Co Ltd	受信装置
US6403596B1 (en)	1999-06-28	2002-06-11	Merck & Co., Inc.	Substituted pyridones having cytokine inhibitory activity
RU2264403C2 (ru)	1999-11-10	2005-11-20	Орто-Макнейл Фармасьютикал, Инк.	Замещенные 2-арил-3-(гетероарил) имидазо [1,2-а] пиримидины, содержащие их фармацевтические композиции и связанные с ними способы
MXPA02004735A (es)	1999-11-12	2003-01-28	Orive Javier Uhthoff	Compuestos heteroaromaticos, biciclicos y triciclicos.
US6602872B1 (en)	1999-12-13	2003-08-05	Merck & Co., Inc.	Substituted pyridazines having cytokine inhibitory activity

2002
- 2002-11-15 US US10/298,205 patent/US6921762B2/en not_active Expired - Fee Related
- 2002-11-16 PT PT02789671T patent/PT1448564E/pt unknown
- 2002-11-16 CA CA002466072A patent/CA2466072A1/en not_active Abandoned
- 2002-11-16 DK DK02789671T patent/DK1448564T3/da active
- 2002-11-16 WO PCT/US2002/036699 patent/WO2003044021A2/en not_active Ceased
- 2002-11-16 AU AU2002352722A patent/AU2002352722B2/en not_active Ceased
- 2002-11-16 EP EP02789671A patent/EP1448564B1/de not_active Expired - Lifetime
- 2002-11-16 ES ES02789671T patent/ES2262879T3/es not_active Expired - Lifetime
- 2002-11-16 DE DE60210805T patent/DE60210805T2/de not_active Expired - Fee Related
- 2002-11-16 PL PL02371428A patent/PL371428A1/xx not_active Application Discontinuation
- 2002-11-16 MX MXPA04004552A patent/MXPA04004552A/es active IP Right Grant
- 2002-11-16 JP JP2003545658A patent/JP2005518358A/ja active Pending
- 2002-11-16 AT AT02789671T patent/ATE323705T1/de not_active IP Right Cessation
2006
- 2006-06-16 CY CY20061100809T patent/CY1105053T1/el unknown

Also Published As

Publication number	Publication date
US6921762B2 (en)	2005-07-26
EP1448564B1 (de)	2006-04-19
AU2002352722B2 (en)	2006-10-12
CA2466072A1 (en)	2003-05-30
JP2005518358A (ja)	2005-06-23
ES2262879T3 (es)	2006-12-01
DE60210805T2 (de)	2006-09-14
DK1448564T3 (da)	2006-08-21
MXPA04004552A (es)	2004-08-13
EP1448564A2 (de)	2004-08-25
AU2002352722A1 (en)	2003-06-10
WO2003044021A3 (en)	2003-12-18
PT1448564E (pt)	2006-06-30
CY1105053T1 (el)	2010-03-03
PL371428A1 (en)	2005-06-13
WO2003044021A2 (en)	2003-05-30
DE60210805D1 (de)	2006-05-24
US20030195221A1 (en)	2003-10-16

Legal Events

Date

Code

Title

Description

2006-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1448564

Country of ref document: EP

2009-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60210805D1 (de)	2006-05-24	Substituierte indolizinähnliche verbindungen und ihre verwendung
ATE389636T1 (de)	2008-04-15	Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung
ATE320426T1 (de)	2006-04-15	Harnstoffderivate und ihre verwendung
DE69838070D1 (de)	2007-08-23	Substituierte pyridin-derivate als entzündungshemmende mittel
NO20060278L (no)	2006-03-15	Piperazinderivater og fremgangsmater for anvendelse
PT948495E (pt)	2004-08-31	Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo
DE602004015810D1 (de)	2008-09-25	Substituierte isochinolinderivate und anwendungsverfahren
ATE453636T1 (de)	2010-01-15	Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
MXPA05010883A (es)	2006-01-23	Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina.
EE200300324A (et)	2003-12-15	Asendatud alküülamiini derivaadid ja nende kasutamismeetodid
UA86614C2 (ru)	2009-05-12	Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
EA200601212A1 (ru)	2006-10-27	Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
WO2004092116A8 (en)	2005-05-06	Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
EA200401319A1 (ru)	2005-04-28	Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
SI1458393T1 (sl)	2008-10-31	Substituirani diketopiperazini kot antagonisti oksitocina
WO2006041888A3 (en)	2007-09-07	Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
DE60312154D1 (de)	2007-04-12	2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
MX2007004279A (es)	2007-05-16	Triazoles y su uso como antagonistas del receptor b1 de bradiquinina.
EA200501679A2 (ru)	2006-06-30	Фосфонатсодержащие противовоспалительные соединения (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ подавления воспалительной активности (варианты)